Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies
Capsida Biotherapeutics Inc. and UF startup Kate Therapeutics announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs.
Fresh off Raising $150M, Durham Gene Therapy Startup Kriya Acquires Spain-Based Company
Kriya Therapeutics Inc., with dual headquarters in Durham and Palo Alto, Calif., has acquired a gene therapy startup that Kriya says will align with its approach to treating metabolic disease.
Data Licensing Opportunities Abound, but Deals Are Not Without Challenges
It appears, at first glance, like a no-brainer: Universities, particularly those with affiliated health care centers and organizations, have virtually immeasurable stores of data — the kind of data that companies in the forefront of areas like AI, machine learning, and quantum computing would love to have. It seems like an obvious source of significant potential licensing revenue.
However, “obvious” does not equal “easy,” and the barriers TTOs face in discovering, collecting, and developing an inventory of all the potentially valuable data they have are significant.
NovaBone’s New Bioactive Glass Syringe for Foot & Ankle
UF startup NovaBone Products, leader in synthetic biologics, announced the Alachua, Florida, company has made commercially available a new syringe for targeted delivery of its 45S5 bioactive glass putty device for the foot and ankle market. The newly launched syringe comes in both a 2.5cc and a 5cc formulation.
UF Researchers Create Powerful Cancer-Targeting Compound
A team of University of Florida medicinal chemists and cancer biologists has created a chemical compound that powerfully and selectively helped cells dispose of proteins that cause cancer cells to grow.
Confronting Aids in Florida With Artificial Intelligence
A University of Florida research team is playing its part to stop the global HIV epidemic, applying the power of artificial intelligence to medical records to uncover patterns of risk and bias that have left some patients in Florida with poor access to today’s effective treatments — so effective that HIV infections are not sexually transmitted.
NCI Grant: Empowering Advanced Imaging Study to Optimize Lung Cancer Outcomes
With a $3.2 million grant from the National Cancer Institute (NCI), investigators from the newly NCI-designated UF Health Cancer Center and the University of Michigan Rogel Cancer Center will work to close evidence gaps in lung cancer care delivery. Over the five-year project, the team will examine the effectiveness of imaging surveillance strategies based on community-identified needs.
UF Health Shands Transplant Center Programs Among Nation’s Best
With patient outcomes in the nation’s top 10%, the UF Health Shands Transplant Center is once again Florida’s foremost destination for transplants. As of July 2023, five organ transplant types demonstrate exceptional results as evaluated by the Scientific Registry of Transplant Recipients, or SRTR.
NovaBone Products Receives 510(k) Clearance for Wound Dressing for the Advanced Wound Market
NovaBone Products, a UF startup and a leader in synthetic biologics, has received clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Wound Matrix product – first of its kind collagen + 45S5 bioactive glass device for the wound care market.
Positive Results in Cancer Vaccine Trial for Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Morphogenesis, Inc., a biotechnology company focused on developing cancer vaccines, in partnership with CohBar, believes they have met their milestone with IFx-HU2.0, a cancer vaccine studied in advanced Merkel cell carcinoma and squamous cell carcinoma.
